Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment (NCT06069843)
KET-MCI: An Open-label Trial of Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
🩺 Plain-English Summary (8th-Grade Level)
Ketamine is a NMDA-receptor antagonist that promotes synapse formation and has been shown to rapidly improve symptoms in depression. Even a single dose of ketamine has been shown to improve depression and cognition with short-term memory, inhibitory control, cognitive flexibility, and processing speed showing improvements within days of treatment. The mechanism behind ketamine's rapid action is not clear but some groups have speculated it may be related to enhanced neuroplasticity, particularly in the frontal areas and the hippocampus. If this mechanism is accurate, ketamine may be especially effective in treating mild cognitive impairment and depression (MCI-D) where changes in the hippocampus and frontal areas have been implicated. Although few studies have been published on the effects of ketamine in older adults, some small pilot studies suggest that ketamine treatment might be effective in improving depression in older adults and relatively safe. There are no studies looking at the effects of ketamine treatment in patients with MCI-D. The research team hypothesize that IV ketamine treatment will be well-tolerated and will improve depression and cognition in patients with MCI-D. The study team will explore the effects of brain imaging abnormalities and amyloid biomarker status on the responsiveness to ketamine. The study team will conduct an open-label pilot study designed to gather data to support an application for a larger NIH-funded study.
Who can join: Review the eligibility criteria below.
Location: Icahn School of Medicine at Mount Sinai (Depression and Anxiety Center) — New York, New York
Age range: 50 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Icahn School of Medicine at Mount Sinai (Depression and Anxiety Center) — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depression
- Neural Circuit Biomarkers of Transcranial Magnetic Stimulation Study — Stanford, California
- Meditation Accelerated Brain Stimulation for Depression — San Diego, California
- A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers — Houston, Texas
- EEG Biomarker Study for Participants in the Neurolief "MOOD" Trial — Providence, Rhode Island
- Using rTMS to Treat Depression — Miami, Florida
- Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome — Boston, Massachusetts
Explore by condition: All Depression clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.